Real World Experience with Tofacitinib in IBD at a Tertiary Center

BACKGROUND AND AIMS: Many inflammatory bowel disease (IBD) patients do not respond to medical therapy. Tofacitinib is a first in class, partially selective inhibitor of Janus kinase, recently approved for treating patients with ulcerative colitis (UC). We describe our experience with the use of tofa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Dig Dis Sci
Egile Nagusiak: Weisshof, Roni, Golan, Maya A., Sossenheimer, Philip H., Jurdi, Katia El, Ollech, Jacob E., Pekow, Joel, Cohen, Russel D., Sakuraba, Atsushi, Dalal, Sushila, Rubin, David T.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6935176/
https://ncbi.nlm.nih.gov/pubmed/30734234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10620-019-05492-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak